Heartflow (NASDAQ:HTFL) CFO Vikram Verghese Sells 27,540 Shares

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 27,540 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $49.69, for a total value of $1,368,462.60. Following the completion of the sale, the chief financial officer owned 221,143 shares in the company, valued at approximately $10,988,595.67. This represents a 11.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total value of $297,325.60.

Heartflow Stock Performance

Shares of HTFL stock opened at $48.91 on Friday. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $51.78. The firm has a market capitalization of $4.25 billion and a PE ratio of -26.73. The stock has a fifty day moving average of $33.76 and a two-hundred day moving average of $29.92.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.Heartflow’s revenue for the quarter was up 47.7% compared to the same quarter last year. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. bought a new stake in shares of Heartflow during the 3rd quarter worth $48,871,000. Legal & General Group Plc acquired a new position in shares of Heartflow in the 3rd quarter valued at $59,000. Franklin Resources Inc. purchased a new position in Heartflow in the 3rd quarter worth about $10,829,000. UBS Group AG acquired a new stake in Heartflow during the 3rd quarter worth about $5,130,000. Finally, Sei Investments Co. purchased a new stake in Heartflow during the third quarter valued at about $303,000.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HTFL shares. Morgan Stanley increased their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Freedom Capital raised Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Wells Fargo & Company upped their price objective on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.43.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.